Treatment of Severe Atopic Dermatitis with a Combination of Subcutaneous Allergen Immunotherapy and Cyclosporin

다국어 초록 (Multilingual Abstract)

Purpose: The clinical efficacy of subcutaneous allergen immunotherapy (SCIT) for the treatment of patients with severe atopic dermatitis (AD) using house dust mite (HDM) extract has been reported. Cyclosporin has been regarded as an effective medication for treatment of severe AD. In this study, we investigated a clinical usefulness of combined treatment with SCIT and cyclosporin in patients with severe AD. Materials and Methods: Nine patients with severe AD and hypersensitivity to HDM were treated with a combination of SCIT using HDM extract and cyclosporin for 12 months. The primary efficacy outcome was the change in the standardized clinical severity scoring system for AD (SCORAD) values, measured at 6 and 12 months, in comparison with the values at baseline. Daily dose of cyclosporin was decreased or discontinued according to the degrees of clinical improvements in individual patients. Results: In 8 patients who completed 12 months of treatment, the SCORAD values significantly decreased from 71.5±15.5 (mean±SD) at baseline to 20.4±14.6 at 6 months and 26.3±13.6 at 12 months (Wilcoxon signed-rank test, p=0.01), and no significant systemic side effects were observed. Cyclosporin was discontinued in 4 of 8 patients within 8 months after starting the combined treatment. Conclusion: In this study, combined treatment with SCIT and cyclosporin resulted in significant clinical improvements in patients with severe AD. Further studies are needed to test the clinical usefulness of this combined treatment for patients with severe AD.

참고문헌 (Reference)

1 Werfel T, "Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study" 61 : 202-205, 2006

2 Nahm DH, "Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex" 146 : 235-240, 2008

3 Buβmann C, "Systemic therapeutic options for severe atopic dermatitis" 7 : 205-219, 2009

4 Czarnecka-Operacz M, "Specific immunotherapy in atopic dermatitis--Four-year treatment in different age and airborne allergy type subgroups" 14 : 230-240, 2006

5 김명은, "Safety of Accelerated Schedules of Subcutaneous Allergen Immunotherapy with House Dust Mite Extract in Patients with Atopic Dermatitis" 대한의학회 26 (26): 1159-1164, 2011

6 Oranje AP, "Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score" 157 : 645-648, 2007

7 Kroot EJ, "Oral pulsed dexamethasone therapy in early rheumatoid arthritis: a pilot study" 1069 : 300-306, 2006

8 Akdis CA, "Mechanisms of allergen-specific immunotherapy" 127 : 18-27, 2011

9 Novak N, "Immune mechanisms leading to atopic dermatitis" 112 : 128-139, 2003

10 Hanifin JM, "Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines”" 50 : 391-404, 2004

11 Krathen RA, "Failure of omalizumab for treatment of severe adult atopic dermatitis" 53 : 338-340, 2005

12 Takiguchi R, "Efalizumab for severe atopic dermatitis: a pilot study in adults" 56 : 222-227, 2007

13 Hanifin JM, "Diagnostic features of atopic dermatitis" 92 (92): 44-47, 1980

14 Akdis CA, "Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report" 118 : 152-169, 2006

15 Schmitt J, "Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis" 21 : 606-619, 2007

16 Simon D, "Anti-CD20 (rituximab) treatment improves atopic eczema" 121 : 122-128, 2008

17 Pipet A, "Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy" 103 : 800-812, 2009

18 Novak N, "Allergen specific immunotherapy for atopic dermatitis" 7 : 542-546, 2007

19 Calderon MA, "Allergen injection immunotherapy for seasonal allergic rhinitis" CD001936-, 2007

20 Bousquet J, "Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper" 102 : 558-562, 1998

21 Abramson MJ, "Allergen immunotherapy for asthma" CD001186-, 2000